カラ・ビオ
KALA BIO, Inc.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -21.32 | $0 | -$2M |
| 2026 Q1 | -7.00 | $0 | -$3M |
| 2025 Q4 | 0.00 | $0 | -$5M |
| 2025 Q3 | -53.50 | $0 | -$11M |
| 2025 Q2 | -85.50 | $0 | -$8M |
| 2025 Q1 | -70.49 | $0 | -$9M |
| 2024 Q4 |
| -1.74 |
| $0 |
| -$5M |
| 2024 Q3 | -1.93 | $0 | -$5M |